問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Digestive System Department

Division of General Surgery

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

林成俊Lin, Chen-Chun
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -4 個月

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林成俊

List

56Cases

2020-04-01 - 2026-05-01

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting4Sites

Terminated4Sites

2020-08-17 - 2023-12-12

Phase I/II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2022-03-31 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting4Sites

2023-01-30 - 2028-11-27

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2023-07-01 - 2026-06-30

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2025-05-01 - 2028-12-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2025-04-01 - 2030-06-18

Phase III

Active
A phase III, randomized, open-label, commissioner-blinded, multicenter trial evaluating ribegostomig in combination with bevacizumab, with or without tremelimumab, as first-line treatment for patients with advanced hepatocellular carcinoma (ARTEMIDE-HCC01).

  • Condition/Disease

    Advanced hepatocellular carcinoma

  • Test Drug

    Atezolizumab Bevacizumab Rilvegostomig (AZD2936) Tremelimumab

Participate Sites
8Sites

Recruiting8Sites

2021-08-01 - 2027-02-28

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-07-01 - 2027-02-26

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2024-03-01 - 2030-03-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB